![]() Menopause: The FDA also approved fezolinetant, sold by Astellas Pharma as Veozah, for the treatment of vasomotor symptoms (aka “hot flashes”) for women undergoing menopause. The deal involves an upfront payment of $75 million to Scribe with the potential for up to $1.5 billion in milestone payments as well as royalties.Īmbient AI: Suki, which uses voice recognition AI for doctors, announced it’s integrating its software with Epic’s electronic health records software.Ĭloud Omics: DNA sequencing company Element Biosciences announced that it’s integrating with genomics cloud platform Amazon Omics, which will enable sequencing data to be streamed directly from Element’s AVITI system.Īlzheimer’s Agitation: The FDA has approved brexpiprazole, which is sold by Otsuka and Lundbeck as Rexulti, for the treatment of the agitation that often accompanies Alzheimer’s-related dementia. Health Guidance: Amino Health, which created a digital platform that helps guide its customers through their healthcare options, has raised $80 million in debt and equity financing.Ĭrispr Medicine: Genetic medicines company Scribe Therapeutics is entering into a collaboration with Lilly subsidiary Prevail Therapeutics to accelerate the development of gene therapies against neurological targets. They’re calling the Palo Alto-based startup Hippocratic AI in a nod to the code of ethics doctors take. Shah and seven cofounders have raised a $50 million seed round from General Catalyst and Andreessen Horowitz to develop the large language model that will power all of these different healthcare bots. ![]() None of them, however, will be human – they will all be voice or text chatbots. Munjal Shah envisions a future where everyone has access to a nutritionist, a genetics counselor and a health insurance billing specialist at the touch of a button. ![]() Munjal Shah, cofounder and CEO, Hippocratic AI.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |